| Literature DB >> 26110030 |
Lazaro Alessandro Soares Nunes1, Sayeeda Mussavira2, Omana Sukumaran Bindhu2.
Abstract
This systematic review presents the latest trends in salivary research and its applications in health and disease. Among the large number of analytes present in saliva, many are affected by diverse physiological and pathological conditions. Further, the non-invasive, easy and cost-effective collection methods prompt an interest in evaluating its diagnostic or prognostic utility. Accumulating data over the past two decades indicates towards the possible utility of saliva to monitor overall health, diagnose and treat various oral or systemic disorders and drug monitoring. Advances in saliva based systems biology has also contributed towards identification of several biomarkers, development of diverse salivary diagnostic kits and other sensitive analytical techniques. However, its utilization should be carefully evaluated in relation to standardization of pre-analytical and analytical variables, such as collection and storage methods, analyte circadian variation, sample recovery, prevention of sample contamination and analytical procedures. In spite of all these challenges, there is an escalating evolution of knowledge with the use of this biological matrix.Entities:
Keywords: biological markers; drug monitoring; non-invasive; oral health; saliva
Mesh:
Substances:
Year: 2015 PMID: 26110030 PMCID: PMC4470107 DOI: 10.11613/BM.2015.018
Source DB: PubMed Journal: Biochem Med (Zagreb) ISSN: 1330-0962 Impact factor: 2.313
Diagnostic kits based on salivary omics.
| Strand Germline Cancer Test | Cancer risk assessment | DNA | Targets entire coding regions of the | |
| CTGT connective tissue gene test | Achondroplasia (ACH) / Hypochondroplasia (HCH) | DNA | Sanger Sequencing or Deletion / Duplication or Sanger / Del Dup Comprehension | |
| Ambry GeneticsTM | Familial Hypercholesterolemia | DNA | Deletion/Duplication Analysis | |
| JScreen | Tay Sachs screening | DNA | Gene Sequencing | |
| Sickle Cell Anemia Mutation Detection Test | Sickle Cell Anemia detection | DNA | Sanger Sequencing | |
| Oral Fluid NanoSensor Test (OFNASET) | Determination of various diseases | Nucleic acids and protein | Polymer Micropatterned electrodes Electric-induced deposition | |
| Ora Quick ADVANCE Rapid HIV-1/2 Antibody Test (OraSure Technologies, Bethlehem, Pa.) | Screening and risk assessment test for HIV | Protein | Detects antibodies to HIV-1 and HIV-2 | |
| VigilantBIO | Oral cancer screening | Hyaluronic acid, hyaluronidase and CD44 | Detects specific protein markers | |
| SaliMarkTM OC (PeriRx LLC) | Oral cancer risk assessment | Certain discrete biomarkers and proteins | Elevation of combinations of biomarkers which are consistent with an increased risk of oral cancer | |
| MyPerioPath® | Periodontal disease | Bacteria | Identifies the type and concentration of specific perio-pathogenic bacteria that are known to cause periodontal disease | |
| OraRisk® HPV | Oral Human Papillomavirus | Viral | Identifies the type(s) of oral HPV |
Transport mechanism of saliva components into the salivary gland.
| Ultrafiltration through gap junctions between secretory cells | Molecules < 1.9 kDa (ions, water and some peptides) |
| Selective transport via passive diffusion | Lipophilic molecules (steroid hormones) |
| Active transport through ion channels | Ions (Na+, K+, Cl- and HCO3-) |
| Water channels (Aquaporins) | Water |
| Synthesized and secreted in acinar or ductal cells | Organic components (lysozyme, lactoferrine, peroxidases, cystatins, histatins, immunoglobulin A, salivary alpha amylase) |
Adapted from Aps and Martens ().
Main functions of saliva and its components.
| Teeth | Inhibition of demineralization | MUC |
| Remineralization | PRPs, statherin, calcium, phosphate | |
| Lubrication, elasticity, stickiness and viscosity | PRPs, MUC5B, MUC7 | |
| Buffering | HCO3-, K+, proteins | |
| Food | Digestion | SAA, lipase, protease, DNAse, RNAse |
| Taste | Zinc | |
| Bolus | MUC | |
| Micro- | Anti-viral | MUC5B, MUC7, IgA, cystatin A |
| Anti-bacterial | MUC5B, MUC7 lysozyme, lactoferrin, lactoperoxidase, histatins, cystatin A, catalase |
Adapted from Amerongen et al. (). MUC – mucin; PRPs - proline-rich proteins; MUC5B - mucin type 5B; MUC7 - mucin type 7; SAA - salivary alpha amylase.
Comparison of saliva and blood analytes in different studies.
| Na+ (mmol/L) | Unstimulated Plastic | 3.0-29.01 | 136.0-145.01 | FP | ( |
| K+ (mmol/L) | Unstimulated Plastic | 6.4-36.61 | 3.5-4.51 | ISE | ( |
| Ca2+ (mmol/L) | Unstimulated Plastic | 0.88-2.51 | 1.15-1.331 | ISE | ( |
| Cl- (mmol/L) | Unstimulated Plastic | 0-271 | 98-1071 | ISE | ( |
| UA (mmol/L) | Stimulated Liquid (SCS®) | 0.07-0.321 | 0.24-0.49 | Enzymatic | ( |
| Urea (mmol/L) | Unstimulated Polypropylene | 1.66-7.51 | 2.16-8.21 | Enzymatic | ( |
| Protein (g/L) | Stimulated Liquid (SCS®) | 0.17-1.501 | 60-801 | 36:30 a.m. Colorimetric | ( |
| Stimulated Liquid (SCS®) | 0.18-5.301 | 34:00 p.m. Colorimetric | ( | ||
| TAS (μmol/L) | Stimulated Liquid (SCS®) | 42-4071 | 489-7761 | FRAP | ( |
| SAA | Stimulated Liquid (SCS®) | 5.0-155.41 | not reported | 36:30 a.m. Enzymatic | ( |
| Stimulated Liquid (SCS®) | 24.0-368.01 | not reported | 34:00 p.m. Enzymatic | ( | |
| LD (U/L) | Unstimulated Plastic | 113-6091 | 180-3601 | Enzymatic | ( |
| Cortisol (nmol/L) | Unstimulated Polystyrene | 10.9-40.31 | 17-441 | 36:00–8:00 a.m. | ( |
| Stimulated Cotton (Salivette®) | 3.57-35.11 | 35:30-8:30 a.m. | ( | ||
| Stimulated Cotton (Salivette®) | 1.14-10.31 | 36:00 p.m. | ( | ||
| Stimulated Cotton (Salivette®) | <3.0 | 311:00-12:00 p.m. | ( | ||
| DHEA (nmol/L) | Stimulated Cotton (Salivette®) | 1.5±0.32 | 0.6-39.41 | RIA | ( |
| Free testosterone (pg/mL) | Unstimulated Plastic | 18.71±5.012 | 52.0-280.01 | RIA | ( |
1Reference interval (2.5th and 97.5th percentile); 2mean ± standard deviation; 3specific collection time mentioned due to influence by daily circadian rhythm. FP – flame photometry; ISE – ion selective electrode; UA – uric acid; SCS® – Saliva Collection System (Greiner-Bio One); FRAP – ferric reducing ability of plasma method; TAS – total antioxidant status; SAA – salivary alpha amylase; LD – lactate dehydrogenase; DHEA – dehydroepiandrosterone; RIA – radioimmunoassay; LC-MS – liquid chromatography-tandem mass spectrometry.
Comparison of saliva with other body fluids / tissue for measurement of various analytes in selected pathological conditions.
| Head and neck cancer | Saliva – tumor tissue | Mitochondrial DNA | Positive | Increased levels that decreased in post-surgical condition | ( |
| OSCC | Saliva-serum | p53 antibody | Positive | Saliva may offer a specific method for detection of a subset of OSCC with p53 aberrations | ( |
| Malignant ovarian tumors | Saliva-serum | CA 125 | Positive | Saliva assay showed better assay value than serum | ( |
| Breast cancer | Saliva-serum | Cellular erythroblastosis oncogene B-2 (c-erbB-2) | Positive | ErbB-2 protein may have potential use in the initial detection | ( |
| Dengue | Saliva-serum | Dengue antibody | Positive | Saliva as an alternative for dengue diagnosis | ( |
| Sjögren’s syndrome | Saliva- serum | C-X-C motif chemokine 13 | Positive | CXCL13 may provide an innovative approach for managing this disease | ( |
| HIV | Saliva-serum | HIV antibody | Positive | Formulation of a commercially available diagnostic kit OraQuick | ( |
EGF - epidermal growth factor; HIV - human immuno deficiency virus.
Salivary markers identified through omic disciplines.
| Transcriptomics | Cyclin 1↑, Epidermal growth factor receptor↑, Fibroblast growth factor 19↑, Fibroblast growth factor substrate 2↑, Growth regulation by estrogen in breast cancer 1↑, 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha↓, Beta-2-microglobulin↓, Brain acid-soluble protein 2↓, Immediate early response 3↓, IL1B↓, IL-8↑, IL-1β↑, Spermidine/spermine N1-acetyltransferase 1↑, S100 calcium binding protein P↑ | ( |
| Proteomics | Maspin↑, Stathmin↑, Transketolase↑, Dimethyladenosine transferase↑, v-Ha-ras oncogene↑, Type I collagen pro alpha↓, Tumor necrosis factor↓, Alpha-1-B-glycoprotein*, Complement factor B proteins*, Beta fibrin↑, S100 calcium binding protein↑, Transferrin↑, Immunoglobulin heavy chain constant region γ 2↑, Cofilin-1↑, Transthyretin↓, IL-8↑, IL-1β↑, Mac-2-binding protein↑ | ( |
| Metabolomics | Choline↑, Betaine↑, Pipecolinic acid↑, L-carnitine↓, L-leucine↓, L-phenylalanine↓ | ( |
| Proteomics | Proline-rich glycoprotein↓, Secretory immunoglobulin A↑, Histatin-5↑, Lactoperoxidase↑, Statherin↓, Truncated cystatin S↓, Cystatins↓, Lysozyme↓ | ( |
↑ - increased concentration; ↓ - decreased concentration; *parameters appearing only in the defined condition; IL – interleukin.
Disease specific biochemical analytes in saliva.
| Malignancies | SA↑, Long non-coding RNA↑, p53 antibodies*, CA15-3↑, Cellular erythroblastosis oncogene B-2↑, Cancer antigen 125↑, Fibroblast growth factor 2↑, Fibroblast growth factor receptor 1↑, Prostate specific antigen↑, Cortisol↑, LD↑, Nitrate↑, Adenosine deaminase↑, Alpha-defensins↑, Beta-defensins↑, Endothelins↑, Statherins↓, Interleukin-8↑, Thioredoxin↑ | ( |
| DM | Glucose↑ | ( |
| Renal condition | Cortisol↑, Nitrite*, UA*, Alpha-amylase*, Lactoferrin*, Creatinine↑ | ( |
| Sjogren’s Syndrome | Lactoferrin↑, Beta-2-microglobulin↑, Lysozyme C↑, Cystatin C↑, Amylase↓, Carbonic anhydrase↓ | ( |
| Multiple sclerosis | IgA↓ | ( |
| Sarcoidosis | Alpha-amylase↓, Kallikrein↓ | ( |
| Bone turnover markers | Deoxypyridinium↑, Osteocalcin↑, Hepatocyte growth factor↑, Interleukin-1-beta↑, Alkaline phosphatase↑ | ( |
| Cardiovascular diseases | C-reactive protein↑, Myoglobin↑, Creatinine kinase myocardial band↑, Cardiac troponins↑, Myeloperoxidase↑, Tumor necrosis factor α↑, Matrix metalloproteinase–9↑, Intercellular adhesion molecule-1↑, Soluble CD40 ligand↑, Lysozyme↑ | ( |
| Dental caries and periodontal diseases | Aspartate aminotransferase↑, Alkaline phosphatase↑, UA↓, Albumin↓, Polymeric immunoglobulin receptor↓, Actin-related protein 3↓, Carbonic anhydrase VI↓, Interleukin 1 Receptor antagonist↓, Plastin-2↑, Leukocyte elastase inhibitor↑, Immunoglobulin J↑, Immunoglobulin↑, Cystatin S↑, Amylase*, Calprotectin*, Histatins*, Lysozyme↑, Lactoferrin↑, Defensins*, Peroxidases*, PRPs*, MUC*, Prostaglandin E(2)*, Albumin↑, LD↑ | ( |
| Diseases of the adrenal cortex | Cortisol↑ | ( |
| Psychological conditions | SAA↑, Cortisol*, Substance P*, Lysozyme↑, Secretory IgA↓, Testosterone↑ | ( |
| Occupational and environmental medicine | Cortisol↑, IgA↓, Lysozyme↓, Chromogranin↑, SAA↑, Lead↑, Cadmium↑ | ( |
| Infections (bacterial, fungal, viral) | Measles virus-specific IgM↑, HIV—HIV-1*, HIV-2—antibodies*, | ( |
| Cystic fibrosis | Cathepsin-D↑, LD↑ | ( |
| Ectodermal dysplasia | Inorganic constituents↑, Total protein↑ | ( |
| Obesity | CRP↑, Leptin↑, Insulin↑, Adiponectin↓ | ( |
| Metabolic Syndrome | UA↑ | ( |
↑ – increased concentration; ↓ – decreased concentration; *parameters appearing only in the defined condition. SA – sialic acid; Hsp – heat shock proteins; SAA – salivary alpha amylase; HIV – human immuno deficiency virus, MUC – mucins; PRPs – proline-rich proteins; LD – lactate dehydrogenase; UA – uric acid.
Saliva based surveillance for specific drugs.
| Antiepileptic | Levetiracetam (5.6–27.6 µg/mL) | ( |
| Carbamazepine | ( | |
| Phenobarbital and phenytoin | ( | |
| Immuno- | Cyclosporine (8.3 ± 5.2 µg/mL) | ( |
| Respiratory | Theophylline | ( |
| Anti-cancer | Cisplatin and Carboplatin (0.13 and 1.15 mg/L) | ( |
Saliva as a tool in identification of substance abuse.
| Metabolites of substance abuse | Cotinine (major nicotine metabolite) | ELISA / EIA | 0.15 ng/mL | |
| Thiocyanate (cigarette smoking) | Fourier trans-form infrared spectroscopy | 0.83 mmol/liter | ( | |
| D9-Tetrahydrocannabinol (a major psychoactive component of marijuana) | Qualitative YES or NO assay | 25 ng/mL | ||
| Recreational drugs | Cocaine | Qualitative YES or NO assay | 20 ng/mL | |
| Pharmaceutical drugs used as recreational drugs | Amphetamines | Qualitative YES or NO assay | 25 ng/mL | |
| Barbiturates | Gas chromatography | 0.1–1 µg/mL | ( | |
| Benzodiazepines | High performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) | 1.5 ng/mL | ||
| Opioids | Qualitative YES or NO assay | 25 ng/mL | ||
| Phencyclidine | High performance LC-MS/MS | 1 ng/mL |